PMID- 33747940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in 
      Recurrent Merkel Cell Carcinoma.
PG  - 625360
LID - 10.3389/fonc.2021.625360 [doi]
LID - 625360
AB  - BACKGROUND: As angiogenesis is an essential step in tumor growth and metastasis, 
      the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary 
      anticancer therapy across various malignancies. However, its efficiency and 
      safety in Merkel cell carcinoma (MCC) are uncertain. CASE PRESENTATION: The 
      current study described the case of a 91-year-old man who presented with a 3.2 x 
      3.0 x 2.2 cm rapidly growing, solitary tumor of the right lower eyelid. It was 
      diagnosed as MCC pathologically. Twenty-seven days after the surgery, the patient 
      returned to the hospital with recurrent MCC. Apatinib was then administered to 
      this patient. The patient had a complete response (CR) to apatinib after 4.4 
      months of targeted therapy. Twenty-seven months of progression-free survival 
      (PFS) was achieved with controllable treatment-related adverse events (AEs). 
      CONCLUSION: Treatment with apatinib demonstrated clinical benefit in our patient 
      with recurrent MCC, highlighting its potential utility in other MCC patients. 
      Further clinical trials are needed to determine the efficacy and safety of 
      apatinib in MCC patients.
CI  - Copyright (c) 2021 Feng, Song and Jia.
FAU - Feng, Yiyi
AU  - Feng Y
AD  - Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai Key Laboratory of Orbital Diseases and 
      Ocular Oncology, Shanghai, China.
FAU - Song, Xin
AU  - Song X
AD  - Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai Key Laboratory of Orbital Diseases and 
      Ocular Oncology, Shanghai, China.
FAU - Jia, Renbing
AU  - Jia R
AD  - Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai Key Laboratory of Orbital Diseases and 
      Ocular Oncology, Shanghai, China.
LA  - eng
PT  - Case Reports
DEP - 20210303
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7966513
OTO - NOTNLM
OT  - Merkel cell carcinoma
OT  - apatinib
OT  - eyelid
OT  - targeted therapy
OT  - tyrosine kinase inhibitor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/23 06:00
MHDA- 2021/03/23 06:01
PMCR- 2021/01/01
CRDT- 2021/03/22 08:20
PHST- 2020/11/03 00:00 [received]
PHST- 2021/01/25 00:00 [accepted]
PHST- 2021/03/22 08:20 [entrez]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/03/23 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.625360 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 3;11:625360. doi: 10.3389/fonc.2021.625360. eCollection 
      2021.